scholarly journals Imaging Comparison between18F-FDG-PET/CT and18F-Flouroethyl Choline PET/CT in Rare Case of Thymus Carcinoma Exhibiting a Positive Choline Uptake

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Mustafa Takesh ◽  
Stefan Adams
Keyword(s):  
Prostate Cancer ◽  
Fdg Pet ◽  
Rare Case ◽  
Specific Antigen ◽  
Young Patients ◽  
Choline Uptake ◽  
Positive Finding ◽  
Choline Pet ◽  
Pet Tracer ◽  
Pet Ct

It is of great value by using PET imaging in oncology to recognize any atypical uptake not related to the underlying disease. That helps in avoiding the false positive finding and may contribute in extending the application range of used radiopharmaceuticals in further disorders. It is well known that radiolabeled choline is an essential PET tracer used currently in prostate cancer. The physiological choline distribution was described. Nevertheless there is still a lack of studies, which describe this distribution in young patients; given that the radiolabeled choline is generally being used in the field of prostate cancer. Whether the thymus exhibits normally a positive choline uptake or not is still unknown. In particular, it is known that the lymphocytes express high affinity of choline transporter and enzymes involving its metabolism. Some cases of thymus carcinoma exhibiting a positive choline had been reported in the literature, however, mostly using11C-choline. We report a rare case of metastatic thymic carcinoma detected incidentally using18F-choline-PET in a 78-year-old male patient referred with elevation of prostate specific antigen. Moreover we present a comparison pattern with18F-FDG-PET modality, in which18F-choline-PET was turned out to be superior in tumor delineation.

scholarly journals 18F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers

2019 ◽  
Vol 8 (10) ◽  
pp. 1657 ◽  
Author(s):  
Nicoletta Urbano ◽  
Manuel Scimeca ◽  
Antonio Crocco ◽  
Alessandro Mauriello ◽  
Elena Bonanno ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Linear Regression Analysis ◽  
Standardized Uptake Value ◽  
Choline Uptake ◽  
High Grade ◽  
Bone Biomarkers ◽  
Mesenchymal Transition ◽  
Choline Pet ◽  
Pet Ct ◽  
Ct Analysis

The main aim of this study was to investigate the possible association between 18F–choline uptake and histopathological features of prostate biopsies such as the Gleason Group and the expression of both epithelial to mesenchymal transition (vimentin) and bone mineralization (bone morphogenetics protein (BMP)-2, runt-related transcription factor 2 (RUNX2), receptor activator of nuclear factor-κB ligand (RANKL), vitamin D receptor (VDR), and pentraxin 3 (PTX3) in situ biomarkers. To this end, we enrolled 79 consecutive prostate cancer patients that underwent both the 18F–choline PET/CT analysis and the prostate bioptic procedure. The standardized uptake value (SUV) average values were collected from 18F–choline PET/CT analysis whereas Gleason Group and immunostaining data were collected from paraffin-embedded sections. Histological classification showed a heterogenous population including both low/intermediate and high-grade prostate cancers. A significant increase of 18F–choline uptake in high-grade prostate lesions (Gleason Score ≥8) was found. Also, linear regression analysis showed a significant correlation between 18F–choline uptake and the number of vimentin, RANKL, VDR, or PTX3 positive prostate cancer cells. Conversely, we observed no significant association between 18F–choline uptake and the expression of bone biomarkers involved in the early phases of osteoblast differentiation (BMP-2, RUNX2). In conclusion, results here reported can lay the foundation for the use of 18F–choline positron emission tomography (PET)/computed tomography (CT) as a diagnostic tool capable of identifying high-grade prostate cancer lesions expressing bone biomarkers.

Ansprechen auf eine Docetaxel-therapie im LNCaP-Prostata-karzinom-Xenograft-Mausmodell

2013 ◽  
Vol 52 (04) ◽  
pp. 141-147 ◽  
Author(s):  
M. Souvatzoglou ◽  
T. Schuster ◽  
R. Nawroth ◽  
G. Weirich ◽  
U. Treiber ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Line ◽  
Small Animal ◽  
Small Animal Pet ◽  
Control Group ◽  
Choline Uptake ◽  
Animal Pet ◽  
Choline Pet ◽  
Pet Ct ◽  
The Mean

SummaryThe aim of this study was to determine whether [11C]choline can be used for docetaxel therapy response assessment in a LNCaPprostate cancer xenograft mouse model using [11C]choline small-animal PET/CT. Animals, methods: The androgen-dependent human prostate cancer cell line LNCaP was implanted subcutaneously into the left flanks of 17 SCID-mice, 12.5 mg testosterone platelets were implanted in the neck wrinkle. All mice were injected 4–6 weeks after xenograft implantation with 37 MBq [11C]choline via the tail vein. Dynamic imaging was performed for 60 minutes with a small-animal PET/CT scanner. After the first [11C]choline PET/CT imaging 8 mice were subsequently injected intravenously with docetaxel twice (days 1 and 5) at a dose of 3 mg/kg body weight. 8 mice were treated with PBS as a control. [11C]choline PET/CT imaging was performed on day 7, 14 and 21 after treatment. Image analysis was performed using tumor/ muscle (T/M) ratios (ROIT/ROIM = T/M ratio). Results: All LNCaP tumours could be visualized by [11C]choline PET/CT. Before treatment the mean T/M ratio was 2.0 ± 0.2 in the docetaxel-treated group and 1.9 ± 0.2 in the control group (p = 0.837). There was a reduction in the mean [11C]choline uptake after docetaxel treatment of the tumours of the LNCaP cell line as early as 1 week after initiation of therapy (T/Mmean ratio 1.5 ± 0.2 after one week, 1.3 ± 0.2 after 2 weeks and 1.4 ± 0.2 after 3 weeks). There was no decrease in [11C]choline uptake in the control group. Conclusion: Our results show that [11C]choline has the potential for use in the early monitoring of the therapeutic effect of docetaxel in a LNCaP prostate cancer xenograft animal model.

The Optimal Timing to Perform 18F/11C-Choline PET/CT in Patients with Suspicion of Relapse of Prostate Cancer: Trigger PSA versus PSA Velocity and PSA Doubling Time

2014 ◽  
Vol 29 (4) ◽  
pp. 423-430 ◽  
Author(s):  
Ferdinando Calabria ◽  
Domenico Rubello ◽  
Orazio Schillaci
Keyword(s):  
Prostate Cancer ◽  
Doubling Time ◽  
Short Communication ◽  
Specific Antigen ◽  
Serum Levels ◽  
Optimal Time ◽  
Optimal Timing ◽  
Choline Pet ◽  
Pet Ct ◽  
Psa Velocity

In the present short communication we considered the main publications focused on trigger prostate-specific antigen (PSA) and PSA kinetics that systematically compared 18F to 11C-choline PET/CT in order to establish the optimal time to perform choline PET/CT in relation to the trigger values and velocity, as well as doubling time of PSA serum levels.

scholarly journals Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT

2021 ◽  
pp. 520-524
Author(s):  
Kazuhiro Kitajima ◽  
Shingo Yamamoto ◽  
Masayuki Fujiwara ◽  
Yusuke Kawanaka ◽  
Yusuke Yamada ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Metabolic Response ◽  
Choline Uptake ◽  
Castration Resistant Prostate Cancer ◽  
Choline Pet ◽  
Metastatic Lesions ◽  
Radium 223 ◽  
Positron Emission ◽  
Pet Ct

We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on 11C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment effect and to determine the viability of bone metastases, regardless of whether sclerosis was present or not. Because one case demonstrated disappearance of abnormal 11C-choline uptake of osteoblastic metastatic lesions after abiraterone therapy and no new lesions at other sites, suggesting nonviable bone metastases, we can assume a complete metabolic response. Because the other case demonstrated a decrease in the existing, abnormal 11C-choline uptake of osteoblastic metastatic lesions, but multiple new appearances of osteoblastic and nonosteoblastic lesions with abnormal 11C-choline uptake after radium-223 therapy suggesting multiple viable bone metastases, we can assume progressive metabolic disease. 11C-choline PET/CT could help in assessing the treatment response of bone metastases in patients with metastatic CRPC.

Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer

2011 ◽  
Vol 32 (6) ◽  
pp. 475-478 ◽  
Author(s):  
Paolo Castellucci ◽  
Chiara Fuccio ◽  
Maria Cristina Marzola ◽  
Adil Al-Nahhas ◽  
Domenico Rubello ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Primary Treatment ◽  
Biochemical Relapse ◽  
Choline Pet ◽  
Pet Ct

Identification of bone involvement in patients with prostate cancer recurrence using 18F-fluciclovine PET/CT and impact on subsequent management.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 248-248
Author(s):  
Michael S Kipper ◽  
Paul Dato ◽  
Keyword(s):  
Prostate Cancer ◽  
Prospective Trial ◽  
Specific Antigen ◽  
Cancer Recurrence ◽  
Bone Lesions ◽  
Curative Intent ◽  
Pet Tracer ◽  
Pet Ct ◽  
Prostate Cancer Recurrence ◽  
The Impact

248 Background: Bone is the most frequent site of metastasis in prostate cancer. Accurate localization of recurrence following primary treatment can help optimize salvage therapy. Positron emission tomography (PET) tracer, 18F-fluciclovine, is approved in Europe and the US for men with rising prostate specific antigen (PSA) after prior treatment. LOCATE was a prospective trial to study the impact of 18F-fluciclovine PET/computed tomography (PET/CT) on management of men with prostate cancer recurrence and negative standard imaging after curative intent treatment. Here, we explore changes in management (CIM) in men with 18F-fluciclovine-avid bone lesions. Methods: 18F-Fluciclovine PET/CT was performed and interpreted according to standard practice at 15 US centers. Eligible men (≥ 18 y; prior curative intent treatment of prostate cancer; recurrence based on rising PSA; negative/equivocal findings on standard bone and pelvic imaging) had their treatment plans recorded pre- and post-scan. Results: A total of 213 men (median pre-scan PSA, 1.0 ng/mL) were enrolled. Overall, 18F-fluciclovine detected lesions in 122 (57%) and 126 (59%) had CIM post-scan. 18F-Fluciclovine-avid bone lesions were found in 23 (11%) men. Prior to the fluciclovine scan, 21 (91%) had a 99mTc-MDP scan (20 negative, 1 equivocal results), 1 (4%) had an unspecified bone scan (negative result) and 1 (4%) did not receive a bone-specific scan. Of the 23 men with positive scans, 15 (65%) had post-scan CIM: ADT added to planned radiotherapy (RT; 4, 27%); ADT replaced with targeted treatment of fluciclovine-positive extrapelvic bony areas (4, 27%); RT modified to target fluciclovine-positive areas (4, 27%); modified ADT regime (2, 13%); and watchful waiting in favor of RT (1, 7%). The majority of men with no post-scan CIM were prescribed ADT (6/8, 75%). Conclusions: Despite negative standard bone imaging,18F-fluciclovine localized recurrence of prostate cancer to bone in 11% of patients; the majority of whom had a management change as a result, frequently in order to target fluciclovine-positive sites. Further study to investigate the clinical outcomes of such changes is warranted. Clinical trial information: NCT02680041.

scholarly journals Incidental Detection of Occult Thyroid Carcinoma with 11C-Choline PET/CT for High Risk Prostate Cancer

2016 ◽  
Vol 10 (4) ◽  
pp. 217-220 ◽  
Author(s):  
Adama Ouattara ◽  
Tiago Ribeiro de Oliveira ◽  
Serge Holz ◽  
Hannes Van den Bossche ◽  
David Strybol ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Thyroid Carcinoma ◽  
Specific Antigen ◽  
Needle Aspiration ◽  
Adjuvant Radiation ◽  
Choline Pet ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer

We report a case of a 65-year-old male patient with high-risk prostate cancer, re-staged with 11C-choline positron emission tomography/computed tomography (PET/CT) for prostate specific antigen recurrences 3 years after radical prostatectomy and adjuvant radiation therapy. In addition to 2 suspicious presacral lymph nodes which were resected and proven to be metastatic, PET/CT revealed a very high uptake in a calcified thyroid nodule. Evaluation with fine needle aspiration was suspicious for thyroid carcinoma and the patient underwent total thyroidectomy, confirming a non-metastatic encapsulated follicular variant of papillary thyroid carcinoma. To our knowledge, this is the first report of a thyroid cancer diagnosed with 11C-choline PET/CT for prostate cancer staging.

Rare Case of Bilateral Adrenal Metastasis from Poorly Differentiated Prostate Cancer Detected Using F-18 FDG PET/CT

2018 ◽  
Vol 5 (1) ◽  
pp. 1-3
Author(s):  
Koramadai Karuppusamy Kamaleshwaran ◽  
Stuart More ◽  
Raghi Paramben Jose ◽  
Ajit Sugunan Shinto
Keyword(s):  
Prostate Cancer ◽  
Fdg Pet ◽  
Rare Case ◽  
Adrenal Metastasis ◽  
Pet Ct ◽  
Poorly Differentiated ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document